Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study
Guillot J, Justice A, Gordon K, Skanderson M, Pariente A, Bezin J, Rentsch C. Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study. Journal Of General Internal Medicine 2024, 1-10. PMID: 38831248, DOI: 10.1007/s11606-024-08817-4.Peer-Reviewed Original ResearchMiddle-aged patientsRisk of mortalityVeterans AffairsChronic medicationsVA patient populationIntegrated healthcare systemNational cohort studyAssociated with increased mortalityMiddle-aged individualsMechanism of injuryMiddle-aged peopleAssociated with mortalityInappropriate medicationsBeers criteriaHealthcare systemAttenuate riskCohort studyClinical characteristicsGeneral populationHyperpolypharmacyFollow-upPolypharmacyPatient populationBackgroundThe roleCox modelBlood type as a risk factor for pancreatic ductal adenocarcinoma.
Rahimi Larki N, Skanderson M, Tate J, Levinson R, Hauser R, Brandt C, Yang Y, Justice A, Wang L. Blood type as a risk factor for pancreatic ductal adenocarcinoma. Journal Of Clinical Oncology 2024, 42: 10559-10559. DOI: 10.1200/jco.2024.42.16_suppl.10559.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinoma riskVeterans Health AdministrationRisk of pancreatic ductal adenocarcinomaNon-O blood typeNeighborhood-level socioeconomic dataIntegrated healthcare systemHigh risk of pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaAssociated with higher riskAssociated with increased riskUnited StatesHealth AdministrationOutpatient encountersHealthcare systemBaseline ageAlcohol useIndex dateAssociation of blood typeCancer deathWhite populationSocioeconomic dataBlack patientsDiverse populationsRisk factorsBlood type